About • Project Farma

Who We Are

We provide biomanufacturing strategy and execution to startup and established pharmaceutical companies, advanced therapy companies, academia, hospitals, government agencies, financial institutions, CROs/CMOs, not-for-profit organizations and medical device companies. Our services include turnkey capital projects, tech transfers and facility builds; owner's representation; project and program management; validation; quality, regulatory and compliance; engineering and automation; serialization / track and trace; reliability, compliance and asset management; and more. We are committed to advancing manufacturing to achieve operational excellence and accelerate speed to market for next-generation medicines.

Our Global Footprint

We provide support globally and are currently supporting projects in: Asia, Australia, Europe, Middle East and North America.

Our corporate headquarters is located in Shelton, Connecticut and we provide regional support across the United States. We are currently supporting projects in: California, Colorado, Delaware, Florida, Maryland, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Texas, Utah, Washington D.C., and Wisconsin.

Philanthropy is Built
into our Foundation

As a patient-focused delivery team, we are committed to connecting our team members to patients and their families. Connecting our team to the patients has fostered a culture within our organization that is focused on providing solutions, meeting deadlines and getting results.

Learn More

Anshul founded and steered PF to become a prominent global consultancy specializing in biologics and advanced therapy engineering with 200+ professionals. Anshul’s role extends to overseeing all corporate legal matters as General Counsel. Under Anshul’s guidance, PF pioneered the industrialization of groundbreaking therapeutics, including some of the earliest commercially approved cell and gene therapies, radioligand treatments, RNA-based therapies, and cutting-edge biologics. Additionally, Anshul led PF in acquiring and conducting due diligence on other engineering consulting firms, bolstering the company’s ability to offer comprehensive solutions to drug developers facing manufacturing and technical challenges. PF’s recent achievements include leading 50+ facility builds with a total capital investment exceeding $5 billion, managing 200+ capital projects, and collaborating with 100+ life science companies.

In 2020, Precision Medicine Group acquired PF, making it the cornerstone of Precision ADVANCE. ADVANCE is a collection of services within Precision, uniquely focused on addressing the intricate aspects of research, clinical development, regulatory compliance, manufacturing, and commercialization required to successfully bring complex, innovative therapies to market. Anshul’s commitment to advancing next-generation medicines extends to various boards and philanthropic organizations, including IQHQ, Alliance for Regenerative Medicines, Alliance for mRNA Medicines, Institute for Life Changing Medicines and several patient-advocacy organizations.

Before his tenure at PF, Anshul was an attorney and founded several digital agencies. He was a patent litigator at Jones Day and dedicated pro bono work to help persecuted refugees attain asylum in the United States. He graduated from Purdue University with a Bachelor’s in Computer and Electrical Engineering and earned his law degree from John Marshall Law School. During law school, he clerked for a federal judge in the Northern District of Illinois and was Editor-in-Chief of the Review of Intellectual Property Law.

John Khoury is a seasoned executive and entrepreneur, biologics and advanced therapy expert with a passion for operational leadership and philanthropic impact.

John is the co-founder and EVP of Project Farma (PF), a leading global biologics and advanced therapy engineering consulting firm. His work with PF has been instrumental in industrializing the largest cell and gene therapy manufacturing footprints in the world, and the commercialization of two of the most notable FDA-approved advanced therapies. In totality, he has overseen 50+ facility builds with over $5BB in capital spend, the selection and management of 80+ CDMOs, and facilitated partnerships with 100+ life science organizations including startups, established biologics and cell and gene innovators.

In 2021, Project Farma was acquired by Precision Medicine Group (PMG). John has maintained his role as Executive Vice President strategically spearheading major initiatives for the 200+ team members including organizational structure, finance, marketing, human resources, and growth while maintaining Project’s Farma’s “Patient Focused, People First” core values.

Prior to Project Farma, John started several B2B and B2C companies in the financial, real estate, manufacturing, and consulting sectors. Over a 10-year period, his business acumen and drive facilitated international growth opportunities in the US, EU, Middle East, and China. John is also a champion for patient advocacy and philanthropy. As a philanthropic and servant leader, John has led his team to volunteer 7,000+ hours over the past few years in support of 25+ patient advocacy groups and not-for-profit organizations.